Denied Xolair? You Still Have Options.
Xolair (omalizumab) is a biologic injection used to treat moderate to severe allergic asthma, chronic idiopathic urticaria (CIU, also known as chronic spontaneous hives), and nasal polyps. Insurance denials are common for several reasons: prior authorization requirements are strict, plans often require documented allergy testing results or specific IgE levels to confirm eligibility, and step therapy rules frequently require trying other treatments first. Even when Xolair is clearly the right clinical choice, the paperwork hurdles can lead to an initial denial.
Option 1: Appeal Your Denial
A strong Xolair appeal typically includes IgE lab results, allergy testing documentation, your treatment history, and your doctor's explanation of why you meet the clinical criteria for Xolair. If the denial was for a documentation gap rather than a coverage decision, that's often the fastest problem to fix. Ellen can help you draft your appeal letter.
Option 2: Explore Clinical Trials
Omalizumab research is ongoing, with trials studying Xolair for both its approved indications and new uses in allergic conditions. There are also trials exploring next-generation anti-IgE therapies and related biologics in the allergy space. Participants in qualifying trials often receive the study medication at no cost. Search ClinicalTrials.gov for "omalizumab" or your specific condition to see what's currently enrolling near you.
Option 3: Patient Assistance Programs
Genentech and Novartis, who co-market Xolair, offer the Xolair Access Solutions program for eligible patients facing financial barriers. The Asthma and Allergy Foundation of America (aafa.org) and the American Academy of Allergy, Asthma and Immunology (aaaai.org) also connect people to resources and support for managing allergic conditions.
For a complete guide to Xolair financial assistance — including copay cards, free drug programs, and independent foundations — see our financial assistance page for Xolair.
Ellen can help you figure out your next step. Start with Ellen →
Frequently Asked Questions
Why was Xolair denied?
The most common reasons include missing or incomplete prior authorization, insufficient lab documentation (plans often require specific IgE levels and allergy skin test results), or step therapy requirements that mandate trying other treatments before a biologic is approved. Some plans also have strict criteria around what qualifies as "moderate to severe" for asthma or chronic urticaria. Your denial letter will specify what the plan says was missing or not met.
Can I get Xolair through a clinical trial?
It's possible. Trials studying omalizumab for asthma, chronic urticaria, and emerging indications do exist, and eligible participants may receive the medication at no cost. There are also trials studying next-generation biologics in the same anti-IgE class. Whether a trial is right for you depends on your specific diagnosis, health history, and what's currently enrolling. Talk to your allergist or immunologist, and search ClinicalTrials.gov.
How long does a Xolair appeal take?
Standard appeals are generally decided within 30 days. If your doctor certifies that the situation is medically urgent, the timeline shortens to 72 hours. If your internal appeal is denied, you can escalate to an independent external review, which usually takes up to 45 days. Keeping careful records — including dates, submission confirmations, and responses — will help you stay organized throughout the process. Talk to your doctor before making any decisions about your treatment.